Los Angeles Capital Management LLC Buys 983,018 Shares of DexCom, Inc. $DXCM

Los Angeles Capital Management LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 313.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,296,814 shares of the medical device company’s stock after purchasing an additional 983,018 shares during the quarter. Los Angeles Capital Management LLC owned about 0.33% of DexCom worth $113,199,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. SWS Partners bought a new stake in shares of DexCom in the 2nd quarter valued at about $1,661,000. Baader Bank Aktiengesellschaft purchased a new position in DexCom in the second quarter worth $393,000. Jennison Associates LLC increased its position in shares of DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after purchasing an additional 994,300 shares in the last quarter. Mn Services Vermogensbeheer B.V. lifted its holdings in shares of DexCom by 4.9% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after purchasing an additional 6,800 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of DexCom by 85.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock worth $105,469,000 after purchasing an additional 557,576 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $55.00 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a market capitalization of $21.45 billion, a PE ratio of 38.19, a P/E/G ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $93.25. The company has a fifty day moving average of $69.24 and a two-hundred day moving average of $77.57.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter in the prior year, the firm earned $0.45 EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the transaction, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,383 shares of company stock valued at $434,274 over the last ninety days. Company insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on DXCM. Stifel Nicolaus started coverage on DexCom in a research note on Tuesday, October 21st. They set a “buy” rating and a $85.00 price target on the stock. TD Cowen decreased their price target on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a report on Friday, October 31st. Piper Sandler set a $75.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. UBS Group decreased their price objective on shares of DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. Finally, Mizuho raised their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.86.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.